Astec Lifesciences Ltd
NSE: ASTEC BSE: 533138Chemicals
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]
₹782
52W: ₹512 — ₹991
PE 0 · Book ₹175 · +347% vs bookMarket Cap₹1,743 Cr
Stock P/E—Price to Earnings
ROCE5.47%Return on Capital
ROE25.3%Return on Equity
Div. Yield0%Face Value ₹10
Weaknesses
- −Stock is trading at 4.17 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -4.18% over past five years.
- −Company has a low return on equity of -26.1% over last 3 years.
- −Company might be capitalizing the interest cost
- −Company has high debtors of 202 days.
Shareholding Pattern
Promoters71.97%
FIIs0.03%
DIIs3.33%
Public24.67%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.75% | 66.74%▼0.0 | 66.74% | 70.87%▲4.1 | 70.87% | 72.42%▲1.5 | 71.97%▼0.5 | 71.97% |
| FIIs | 1.03% | 0.53%▼0.5 | 1.2%▲0.7 | 0.25%▼0.9 | 0.02%▼0.2 | 0%▼0.0 | 0.04%▲0.0 | 0.03%▼0.0 |
| DIIs | 3.37% | 4.5%▲1.1 | 5.4%▲0.9 | 4.34%▼1.1 | 4.26%▼0.1 | 4.01%▼0.3 | 3.17%▼0.8 | 3.33%▲0.2 |
| Public | 28.85% | 28.2%▼0.7 | 26.64%▼1.6 | 24.53%▼2.1 | 24.84%▲0.3 | 23.57%▼1.3 | 24.82%▲1.3 | 24.67%▼0.1 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.79 | 153.75 | 69.37 | 98.55 | 93.86 | 119.53 | 91.08 | 73.72 | 124.72 | 158.62 |
| Expenses | 69.12 | 141.04 | 115.62 | 118.28 | 99.6 | 114.01 | 102.07 | 80.39 | 120.72 | 149.46 |
| Operating Profit | -18.33 | 12.71 | -46.25 | -19.73 | -5.74 | 5.52 | -10.99 | -6.67 | 4 | 9.16 |
| OPM % | -36.09% | 8.27% | -66.67% | -20.02% | -6.12% | 4.62% | -12.07% | -9.05% | 3.21% | 5.77% |
| Net Profit | -24.35 | -0.99 | -39.74 | -38.57 | -40.4 | -16.1 | -33.06 | -24.45 | -15.72 | -7.78 |
| EPS ₹ | -10.87 | -0.44 | -17.74 | -17.22 | -18.04 | -7.19 | -14.76 | -10.97 | -7.06 | -3.49 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹448Cr, up 17.6% YoY. OPM at -1%.
Debt Position
Borrowings at ₹449Cr. Debt-to-equity ratio: 1.22x. High leverage — monitor closely.
Institutional Flow
DIIs: 3.33% (-6.82pp change). FIIs: 0.03% (-1.92pp change). Promoters hold 71.97%.
Margin & Efficiency
ROCE declining from 20% (Mar 2015) to -5% (Mar 2026). Working capital days: -56.
Recent Announcements
- Updates- Grant Of Stock Options 30 Apr
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Apr
- 32Nd AGM 27 Apr - Board approved FY26 audited results, fixed 31 July 2026 AGM, and proposed postal ballot for director appointments and RPTs.
- Book Closure For 32Nd Annual General Meeting 27 Apr - Board approved FY26 audited results, fixed 31 July 2026 AGM, and sought postal ballot approvals.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 Apr - Astec Lifesciences announced Q4 FY26 and FY26 audited results; FY26 income ₹453.2 crore, loss ₹80.9 crore.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse